Heron Therapeutics Inc. (NASDAQ:HRTX) shares shot up 2.8% during trading on Tuesday . The company traded as high as $19.95 and last traded at $19.27, with a volume of 327,965 shares traded. The stock had previously closed at $18.74.

A number of brokerages have commented on HRTX. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Jefferies Group restated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, April 28th. Cantor Fitzgerald restated a “buy” rating on shares of Heron Therapeutics in a research note on Sunday, May 8th. Noble Financial restated a “buy” rating and set a $51.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, April 20th. Finally, Brean Capital restated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $50.30.

The firm’s 50 day moving average is $17.59 and its 200 day moving average is $18.87.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. Equities analysts predict that Heron Therapeutics Inc. will post ($3.73) EPS for the current fiscal year.

A number of large investors have modified their holdings of the company. Bank of Montreal Can acquired a new stake in shares of Heron Therapeutics during the fourth quarter worth about $3,010,000. GAM Holding AG boosted its stake in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares in the last quarter. California Public Employees Retirement System boosted its stake in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock worth $2,419,000 after buying an additional 81,200 shares in the last quarter. Swiss National Bank acquired a new stake in shares of Heron Therapeutics during the fourth quarter worth about $1,100,000. Finally, California State Teachers Retirement System boosted its stake in shares of Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares in the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.